Pilot study to analyze the exhalation profile of patients with graft versus host disease (GvHD) of the lung after allogeneic stem cell transplantaion

Pilot study to analyze the exhalation profile of patients with graft versus host disease (GvHD) of the lung after allogeneic stem cell transplantaion - GvHD exhalate

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006883

Enrollment

Registered

2015-01-27

Start date

2015-01-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T86.00

Interventions

Group 1: pulmonary GVHD: One-time execution of ENose and IMS measurement and one blood sampling Group 2: no pulmonary GVHD: One-time execution of ENose and IMS measurement and one blood sampling

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Review Group (V.A. lung GvHD): -Z.n. allogeneic stem cell or bone marrow transplantation -a GVHD of the lung is assumed by: > respiratory symptoms > Change in lung function e.g. FEV1 120%), > Exclusion of infectious complications by CT thorax (clinical routine / no study examination), laboratory diagnostics (CRP, PCT), infectiological diagnosis (CMV PCR, blood culture, sputum, if necessary) > CT morphological suspicion by wall thickening of the small airways or bronchiectasis > after clinic exclusion of cardiac causes (ECG and UKG) > if necessary. other manifestations of GVHD comparison group -Z.n. allogeneic stem cell or bone marrow transplantation -not respiratory symptoms -Agreement to study participation

Exclusion criteria

Exclusion criteria: Review Group (V.A. lung GvHD): - Infectious or cardiopulmonary causes pulmonary symptoms. Exclusion by chest CT, inflammation paramters (CRP, PCT), possibly microbiological diagnosis, ECG and UKG comparison group: - Clinical or imaging evidence of pulmonary disease (GvHD, infections, cardiopulmonary disease) in the month prior to the examination

Design outcomes

Primary

Measure	Time frame
Differences in breath condensate	—

Secondary

Measure	Time frame
1 protein concentration in blood 2. volatile organic compounds measured with IMS and eNose	—

Countries

Germany

Contacts

Public ContactUrsula Boas

Universitätsklinikum Giessen und Marburg Innere Medizin, Pneumologie

boasu@med.uni-marburg.de06421 - 5863326

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026